Samsung Biologics to acquire Human Genome Sciences from GSK for $280m.

Samsung Biologics, a contract development and manufacturing organization, agreed to acquire Human Genome Sciences, a biopharmaceutical company, from GSK, a global healthcare company, for $280m. “This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics. This marks an important step forward in our mission to achieve a better life through biomedicines, and we look forward to building on the legacy of this facility as we welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact,” John Rim, Samsung Biologics CEO and President.